GlaxoSmithKline Pharmaceuticals Limited (GSK) announces its financial results for the third quarter ended 31st December 2023
Mumbai, India: GlaxoSmithKline Pharmaceuticals Ltd (GSK) reported revenue from operations for the quarter at Rs 805 crores, Profit before exceptional Items and tax at Rs 228 crores with EBITDA margins at 27%.
In a flat General Medicines represented market during the quarter, GSK recorded 1% value growth despite the NLEM impact. Augmentin improved its market share and retained no. 1 rank in the IPM (Indian Pharmaceutical Market). Vaccines market and portfolio continued to deliver sequential growth. GSK will continue to invest in building newer capabilities to improve reach and access for its innovative portfolio comprising Shingrix, Nucala and Trelegy.
Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, "We remain committed to new category development in areas like Adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India. We will continue to drive operational efficiency and explore new innovative solutions including Omnichannel Strategy to expand reach and coverage to the target segments."
About GlaxoSmithKline Pharmaceuticals Limited:
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. For more information, visit GSK-India.com.
Media Contact:
Ransom D' Souza - ransom.a.dsouza@gsk.com
Communications & Government Affairs
